{"disease":{"id":"transthyretin-cardiac-amyloidosis","name":"transthyretin cardiac amyloidosis"},"drugs":{"marketed":[{"drug_id":"tafamidis","indication_name":"Wild-type transthyretin cardiac amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"tafamidis","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":"1430.0","mechanism":"Vyndaqel works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."},{"drug_id":"vyndaqel","indication_name":"Wild-type transthyretin cardiac amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"Tafamidis Meglumine","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin (TTR)","drug_class":"Transthyretin stabilizer","quality_score":10,"revenue":null,"mechanism":"Tafamidis selectively stabilizes TTR tetramer by binding at thyroxine sites, slowing monomer dissociation."},{"drug_id":"tafamidis-test","indication_name":"Wild-type transthyretin cardiac amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"tafamidis-test","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":null,"mechanism":"Vyndaqel works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."},{"drug_id":"vyndamax","indication_name":"Wild-type transthyretin cardiac amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"Tafamidis","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":null,"mechanism":"Vyndaqel stabilizes the Transthyretin protein, preventing its misfolding and aggregation into amyloid fibrils."}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06328075","title":"Artificial Intelligence to Assist the Echocardiographic Identification of Transthyretin Cardiac Amyloidosis","phase":"","overall_status":"UNKNOWN","enrollment_count":15000,"lead_sponsor_name":"Algalarrondo Vincent","has_results":false},{"nct_id":"NCT05772091","title":"Prognostic Value of Echocardiographic Parameters Based on Machine Learning Approach","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Pr. Nicolas GIRERD","has_results":false},{"nct_id":"NCT05064839","title":"Imaging for the Evaluation of Transthyretin Cardiac Amyloidosis Prevalence of Patients Over 65 Hospitalized in Cardiology Wards (the IMPACT Study)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":553,"lead_sponsor_name":"Poitiers University Hospital","has_results":false},{"nct_id":"NCT07306949","title":"Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT04276220","title":"Prevalence of wtATTR-CM After Carpal Tunnel Release Surgery","phase":"NA","overall_status":"COMPLETED","enrollment_count":109,"lead_sponsor_name":"Steen Hvitfeldt Poulsen","has_results":false},{"nct_id":"NCT04601051","title":"Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Intellia Therapeutics","has_results":false},{"nct_id":"NCT05797857","title":"Exercise Training in Transthyretin Cardiac Amyloidosis","phase":"NA","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT05489523","title":"Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT05023889","title":"Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy","phase":"EARLY_PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10,"lead_sponsor_name":"Austin Neuromuscular Center","has_results":false},{"nct_id":"NCT04899180","title":"Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"Mayo Clinic","has_results":false}],"total":10},"guidelines":[],"source":"Drug Landscape verified database"}